France to Reimburse Anti-Obesity Drugs Wegovy and Mounjaro Starting Monday

June 14, 2026 5:26pm

France's Assurance-maladie begins reimbursing 65% of Wegovy and Mounjaro treatments for eligible obese patients this Monday.

Key details

• Assurance-maladie will cover 65% of costs for Wegovy and Mounjaro starting Monday.
• Coverage applies to patients with massive obesity without comorbidities or severe obesity with comorbidities.
• Only specialized physicians can issue the initial prescription for these medications.
• The policy aims to financially support patients requiring obesity treatment.

Starting Monday, the French national health insurance system, Assurance-maladie, will reimburse 65% of costs for the anti-obesity medications Wegovy and Mounjaro. This policy targets patients suffering from massive obesity without comorbidities as well as those with severe obesity accompanied by comorbidities. The initiative aims to reduce the financial burden for patients requiring medical assistance for obesity treatment. However, initial prescriptions can only be issued by specialized doctors, ensuring appropriate medical oversight. This new reimbursement scheme marks a significant step by France to support obese patients in managing their health through these advanced treatments.

This article was translated and synthesized from French sources, providing English-speaking readers with local perspectives.